title: Antibacterial effect and cytotoxicity of beta-1,3-1, 4-glucanase from endophytic Bacillus subtilis SWB8.
abstract: OBJECTIVE
  We studied the antibiotic activity and selective cytotoxicity of beta-1,3-1,4-glucanase from endophytic Bacillus subtilis SWB8.
  
  
  METHODS
  Based on gel permeation chromatography, sodium dodecyl sulfate-polyacrylamide gel electrophoresis and liquid chromatography-tandem mass spectrometry methods, protein fragments of beta-1,3-1,4-glucanase from endophytic Bacillus subtilis strain SWB8 were purified and identified. Then, beta-1,3-1,4-glucanase was used to evaluate the antimicrobial activity against Staphylococcus aureus, Enterococcus faecalis, Bacillus subtilis, Escherichia coli, Salmonella typhi, Salmonella paratyphi A, Shigella dysenteriae, Candida albicans and Cryptococcus neoformans and cytotoxicity against human pulmonary adenocarcinoma cells (A549) and human bone marrow mesenchymal stem cells (MSCs) by using the disc diffusion, methyl thiazolyl tetrazolium and flow cytometry methods, respectively.
  
  
  RESULTS
  Bacterial beta-1,3-1,4-glucanase showed broad antimicrobial spectrum against all nine bacterial and fungal strains. Furthermore, beta-1,3-1,4-glucanase possessed significant anticancer activity against A549 cells that the IC50 and IC90 values were 11.5 and 20.1 microg/mL, respectively. The percentage of apoptotic A549 cells treated with different concentrations of beta-1,3-1,4-glucanase was significantly increased from 4.43% of the control to 43.1% of 19.2 microg/mL glucanase in a dose dependent manner. In contrast, these changes could not be observed in human bone marrow mesenchymal stem cells.
  
  
  CONCLUSIONS
  Beta-1,3-1,4-glucanase could be a potential source of desirable antimicrobial agent, or anticancer compounds with higher efficiency and lower toxicity.
authors.affiliation: Laboratory of Invertebrate Pathology and Applied Microbiology, College of Biotechnology, Southwest University, Chongqing 400715, China. JZX8801150@126.com
authors.forename: Zhixiong
authors.initials: Z
authors.lastname: Jin
authors.forename: Wei
authors.initials: W
authors.lastname: Zhou
authors.forename: Ya
authors.initials: Y
authors.lastname: Wang
authors.forename: Yan
authors.initials: Y
authors.lastname: Wang
authors.forename: Wenjing
authors.initials: W
authors.lastname: Li
authors.forename: Chaojin
authors.initials: C
authors.lastname: Shi
authors.forename: Yonggui
authors.initials: Y
authors.lastname: Liu
authors.forename: Yongji
authors.initials: Y
authors.lastname: Wan
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy; D000077192:Adenocarcinoma of Lung; D000595:Amino Acid Sequence; D000900:Anti-Bacterial Agents / Q000302:isolation & purification* / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000302:isolation & purification / Q000494:pharmacology; D001412:Bacillus subtilis / Q000201:enzymology*; D001419:Bacteria / Q000187:drug effects; D045744:Cell Line, Tumor; D044644:Endo-1,3(4)-beta-Glucanase / Q000302:isolation & purification* / Q000494:pharmacology*; D005658:Fungi / Q000187:drug effects; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D059630:Mesenchymal Stem Cells / Q000187:drug effects; D008969:Molecular Sequence Data; D016415:Sequence Alignment
chemical_list: D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D044644:Endo-1,3(4)-beta-Glucanase